Transcatheter mitral valve repair and replacement; current therapies and general evaluation of new approaches

Abstract

There have been a revolution in catheter based therapies for structural valvular heart diseases in last decade and many incredible improvements in the percutaneous  treatment of mitral and aortic valve diseases. The use of transcatheter mitral valve repair  has gained widespread acceptance in worldwide. More than 50.000 patients have been treated with percutaneous edge-to-edge repair system or annuloplasty systems. Although the most experience has been obtained with MitraClip®, using of percutaneous direct and indirect annuloplasty devices have been on the forefront in recent years. In addition, the percutaneous mitral valve replacement, like the transcathater aortic valve replacement (TAVI), will also be mentioned more in the near future. 

Keywords

• mitral valve,MitraClip,mitral regurgitation

Katater aracılığıyla mitral kapak onarımı ve değiştirilmesi; güncel tedaviler ve yeni yaklaşımların genel değerlendirmesi

Öz

Son on yılda yapısal kalp kapakçık hastalıklarının kateter bazlı tedavilerinde bir evrim meydana gelmiş, mitral ve aort kapak hastalıklarının perkütan tedavisinde inanılmaz birçok  gelişme olmuştur. Transkateter mitral kapak onarımı, dünya çapında yaygın kabul görmüştür. 50000'den fazla hasta perkütan uc-uca tamir sistemi veya perkütan anuloplasti sistemleri ile tedavi edilmiştir. En fazla deneyim MitraClip® ile elde edilmiş olsa da, perkütan direkt ya da indirekt anüloplasti cihazlarının kullanımı son yıllarda ön plana çıkmıştır. Ek olarak, transkatater aort kapak replasmanı (TAVI) gibi perkütan mitral kapak replasmanı da yakın gelecekte daha çok gündeme gelecektir.  

Anahtar Kelimeler

• Mitral kapak,MitraClip,Mitral yetersizlik,Perkütan

References

1. Reference1- Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017; 8: 26. doi: 10.1093/eurheartj/ehx391.
2. Reference2- Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005–1111.
3. Reference3- Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symp¬tomatic, mitral regurgitation who are denied sur¬gery? Eur Heart J 2007; 28: 1358–1365
4. Reference4- Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl JMed 2011; 364: 1395–1406.
5. Reference5- Philip F, Athappan G, Tuzcu EM, et al. MitraClip for severe symptomatic mitral regurgitation in patients at high surgical risk: a comprehensive systematic review. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2014; 84: 581–590.
6. Reference6- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 ;63: e157–185.
7. Reference7- Lipiecki J, Siminiak T, Sievert H, et al. Coronary sinüs based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open heart 2016; 8: 3(2): e000411.
8. Reference8- Maisano F, Taramasso M, Nickenig G, et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J 2016; 37: 817–825.

9. Reference9- Nickenig G, Hammerstingl C, Schueler R, et al. Transcatheter Mitral Annuloplasty in Chronic Functional Mitral Regurgitation: 6-Month Results With the Cardioband Percutaneous Mitral Repair System. JACC Cardiovasc Interv 2016; 10;9(19): 2039-2047.
10. Reference10- Ramlawi B, Gammie JS. Mitral valve surgery: current minimallyNinvasive and transcatheter options. Methodist Debakey Cardiovasc J 2016; 12(1): 20–26.
11. Reference11- Gössl M, Farivar RS, Bae R, et al. Current Status of Catheter-Based Treatment of Mitral Valve Regurgitation. Curr Cardiol Rep 2017; 19(5): 38.
12. Reference12- Guerrero M, Dvir D, Himbert D, et al. Transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification: results from the first multicenter global registry. JACC Cardiovascular interventions 2016; 9: 1361–1371.
13. Reference13- Partida RA, Elmariah S. Transcatheter Mitral Valve Interventions: Current Therapies and Future Directions..Curr Treat Options Cardiovasc Med 2017; 19(5): 32.
14. Reference14- Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 2007; 28(11): 1358-1365.
15. Reference15- Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol 2014; 21;63(2): 185-6.